Albert D Mason Inc. held its stake in shares of Novartis AG (NYSE:NVS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,709 shares of the company’s stock at the end of the second quarter. Albert D Mason Inc.’s holdings in Novartis AG were worth $1,228,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of NVS. Primecap Management Co. CA increased its stake in Novartis AG by 2.1% in the first quarter. Primecap Management Co. CA now owns 21,693,804 shares of the company’s stock worth $1,611,199,000 after buying an additional 446,976 shares during the period. Wells Fargo & Company MN increased its stake in Novartis AG by 12.2% in the first quarter. Wells Fargo & Company MN now owns 9,100,801 shares of the company’s stock worth $675,917,000 after buying an additional 988,301 shares during the period. Parnassus Investments CA increased its stake in Novartis AG by 89.4% in the first quarter. Parnassus Investments CA now owns 8,173,974 shares of the company’s stock worth $593,720,000 after buying an additional 3,858,632 shares during the period. Bank of America Corp DE increased its stake in Novartis AG by 7.5% in the first quarter. Bank of America Corp DE now owns 7,328,730 shares of the company’s stock worth $544,304,000 after buying an additional 508,435 shares during the period. Finally, Fisher Asset Management LLC increased its stake in Novartis AG by 6.3% in the second quarter. Fisher Asset Management LLC now owns 6,505,935 shares of the company’s stock worth $543,050,000 after buying an additional 384,262 shares during the period. 11.27% of the stock is owned by institutional investors and hedge funds.

Shares of Novartis AG (NYSE NVS) traded down 0.97% on Thursday, reaching $83.36. The company’s stock had a trading volume of 696,999 shares. The stock has a 50-day moving average price of $84.23 and a 200-day moving average price of $78.55. Novartis AG has a 1-year low of $66.93 and a 1-year high of $86.90. The company has a market capitalization of $195.30 billion, a price-to-earnings ratio of 30.43 and a beta of 0.73.

Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. During the same period last year, the firm earned $1.23 EPS. The firm’s revenue for the quarter was down 1.8% on a year-over-year basis. On average, equities research analysts forecast that Novartis AG will post $4.73 EPS for the current year.

WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/10/novartis-ag-nysenvs-position-held-by-albert-d-mason-inc.html.

A number of equities research analysts recently commented on NVS shares. TheStreet raised Novartis AG from a “c+” rating to a “b” rating in a report on Friday, June 2nd. Barclays PLC raised Novartis AG from an “underweight” rating to an “equal weight” rating in a report on Thursday, June 22nd. Zacks Investment Research raised Novartis AG from a “strong sell” rating to a “hold” rating in a report on Monday, May 1st. Vetr downgraded Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 target price for the company. in a report on Tuesday, April 25th. Finally, Cowen and Company set a $77.00 target price on Novartis AG and gave the stock a “hold” rating in a report on Tuesday, July 11th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $83.56.

In other Novartis AG news, major shareholder Bioventures Ltd Novartis purchased 266,667 shares of Novartis AG stock in a transaction dated Wednesday, July 5th. The stock was acquired at an average cost of $15.00 per share, with a total value of $4,000,005.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 0.01% of the stock is owned by company insiders.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.